Monocytes and CAR‑T Cell Response in Multiple Myeloma
Official title: Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma
Run by Centre Hospitalier Universitaire, Amiens · NCT07180992 · Data updated 2026-11-12
This project will test whether the number and type of monocytes before and after CAR‑T cell therapy help predict how well CAR‑T works for adults with multiple myeloma.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Drugs / interventions | CART |
| Locations | 1 site (Amiens) |
| Status | Recruiting |
| Started | July 16, 2025 |
| Main results expected | September 2028 |
| Study ends | September 2028 |
| Registry record updated | November 18, 2025 |
| Trial ID | NCT07180992 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18 or older) with multiple myeloma who are scheduled to receive CAR‑T therapy at CHRU Amiens, are affiliated with the social security system, and consent to participate are eligible.
✕Probably not a fit
Patients who are under 18, not receiving CAR‑T therapy, treated outside CHRU Amiens, or unable/unwilling to provide consent or adequate samples are unlikely to receive direct benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will collect blood samples from adults with multiple myeloma who are scheduled to receive CAR‑T cell therapy at CHRU Amiens to measure monocyte counts and surface phenotypes. Samples will be obtained before CAR‑T infusion and at one or more time points afterward, and analyzed using quantitative assays and flow cytometry. Monocyte measures will be correlated with clinical response, relapse timing, and other outcome data to identify patterns linked to better or worse CAR‑T performance. The aim is to identify monocyte-related biomarkers in the tumor microenvironment that relate to CAR‑T durability and relapse risk.
Why it matters
Potential benefit: If successful, findings could help predict which patients are more likely to have a durable response to CAR‑T and guide strategies to improve outcomes.
How similar studies have gone: Previous research has linked monocyte and macrophage activity in the marrow microenvironment to myeloma progression and CAR‑T outcomes, but using monocyte phenotyping as a reliable clinical predictor remains preliminary.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 years old * Treated for a multiple myeloma * CART cells treatment proposed * Affiliated to social security system * Agreed to participate to the study
Where it's running
-
CHRU Amiens
Amiens, France Recruiting
Study contacts
- Study coordinator: Lydia Montes, MD
- Email: Montes.lydia@chu-amiens.fr
- Phone: 33+322088371
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BCMA CAR-T with or without autologous stem cell transplant for young multiple myeloma patients
This will test whether BCMA-directed CAR-T cell therapy, given with or without autologous stem cell transplant (ASCT), helps young women (ages 18–55) with newly diagnosed multiple myeloma.
-
Testing a new CAR-T therapy for multiple myeloma
This study tests a new CAR-T therapy to see if it can help people with tough-to-treat multiple myeloma feel better after other treatments haven't worked.
-
Talquetamab treatment for multiple myeloma after BCMA CAR T-cell therapy
This study is testing if talquetamab can help people with multiple myeloma who haven't improved after receiving BCMA CAR T-cell therapy.
-
T Cell Therapy for Chemotherapy Refractory Multiple Myeloma
This study is testing a new treatment using specially modified immune cells to help adults with hard-to-treat multiple myeloma fight their cancer.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.